Biocad to continue sales of anti-cancer drugs in Sri Lanka despite Roche protests

7 November 2016

Biocad, one of Russia’s largest drugmakers, has won a legal action against pharma giant Roche (ROG: SIX) in the Sri Lanka Court, which was initiated at the request of the Swiss company to ban sales of Biocad’s anti-cancer drugs in Sri Lanka as well as the cancellation of their registration.

At the end of March 2016, Roche appealed to the court of Sri Lanka with a lawsuit against the local distributor of the drugs trastuzumab and bevacizumab, (brand names Herceptin and Avastin, respectively),which are produced by Biocad.

According to Roche, there were substantial violations in the procedure of registration of these drugs in Sri-Lanka. Roche also said that there is currently no evidence that confirms the efficiency and safety of these drugs, due to the lack of clinical trials.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK